A new chance to maintain remission induced by anti-TNF agents in rheumatoid arthritis patients: CynAR study II of a 12-month follow-up

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 1, 2011, Pages 167-174

  Migliore, A ^a   Bizzi, Emanuele ^a   Massafra, U ^a   Vacca, F ^a   Martin Martin, L S ^b   Ferlito, C ^c   Podesta E ^c   Granata, M ^d   Lagana B ^c  

^a S Pietro FBF Hospital   (Italy)

^b REGINA APOSTOLORUM HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

A cyclosporin; Anti tnf; Methotrexate; Remission; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; METHOTREXATE; CREATININE; NONSTEROID ANTIINFLAMMATORY AGENT; CYCLOSPORIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DAS 28 SCORE; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LONG TERM CARE; MALE; MULTICENTER STUDY; PAIN; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; VISUAL ANALOG SCALE; DAS28; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELEVATED BLOOD PRESSURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RELAPSE; URTICARIA; AGED; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COMBINATION;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79957795946     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400119     Document Type: Article

References (23)

1. Spector TD. Epidemiology of the rheumatic diseases. Curr Opin Rheumatol 1993; 5:132-7. (Pubitemid 23098172)
2. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10:1-229.
3. Stone JH, Holbrook JT, Marriott MA, et al. Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54:1608-18.
4. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, Moore B, Wolde D, D'Agati VD. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20:1400-6. (Pubitemid 41430613)
5. Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, Dougados M. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007; 46:327-34. (Pubitemid 46189796)
6. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156:486-91.
7. Van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003; 62:1195-8. (Pubitemid 37500626)
8. Hansen KE, Hildebrand J, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004; 31:1098-102. (Pubitemid 38715884)
9. Haraoui B, Keystone EC, Thorne JC, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004; 31:2356-9. (Pubitemid 39603081)
10. Gómez-Puerta JA, Sanmartí R, Rodríguez-Cros JR, Cañete JD. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis 2004; 63:896. (Pubitemid 38850474)
11. Bennett A, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) 2005; 44:1026-31. (Pubitemid 41487177)
12. Wick M, Ernestam S, Lindblad S, Bratt J, Klareskog L, Van Vollenhoven RF. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy to infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005; 34:353-8. (Pubitemid 41545907)
13. Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23:795-800. (Pubitemid 43040507)
14. Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) 2005; 44:1026-31. (Pubitemid 41487177)
15. Emery P, Kalden JR, Spencer-Green GT, Segrado OG. Adalimumab (HUMIRA) plus Methotrexate induces sustained remission in both early and long-standing rheumatoid arthritis. Arthritis Rheum 2004; 50:S183.
16. European Medicines Agency. Enbrel 25 mg powder and solvent for solution for injection: summary of product characteristics (online). Available from URL: http:www.emea.eu. (Accessed 2006 Sep 5)
17. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41;1552-63. (Pubitemid 28459913)
18. Migliore A, Bizzi E, Massafra U, Vacca F, Martin Martin LS, Ferlito C, Podestà E, Granata M, Laganà B. Can Cyclosporine-A associated to Methotrexate mantain remission induced by antiTNF agents in RA patients? (CynAR pilot study). Int J Immunopathol Pharmacol. 2010; 23:783-90.
19. G Wells, D Haguenauer, B Shea, ME Suarez-Almazor, VA Welch, P Tugwell. Cyclosporine for treating rheumatoid arthritis Cochrane Database of Systematic Reviews 2008 Issue 2
20. Van der Heijde DMFM, van't Hof M, Van Riel PLCM, Van de Putte LBA. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20:579-81. (Pubitemid 23102498)
21. Van Gestel AM, Prevoo ML, Van 't Hof MA, Van Rijswijk MH, Van de Putte LB, Van Riel PL. Development and validation of the European League against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39:34-40. (Pubitemid 26036375)
22. Prevoo ML, van't Hof MA, Kuper HH, Van Leeuwen MA, Van de Putte LB, Van Riel PL. Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:44-48.
23. Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008; 18:460-64.